Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
← catalyst calendarSponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
200actual
Sites
22
Countries
France, Germany, Israel +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2015-01-09 | actual | When the study began enrolling |
| Primary completion | 2025-08-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-21 | actual | The whole study's end, after follow-up |
| First posted | 2014-11-14 | estimated | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non-Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
Interventions
- Drug: Odronextamab multiple dose levels — also filed as REGN1979
- Drug: Odronextamab multiple dose levels — also filed as REGN1979
Primary outcomes
what the primary-completion date above is the date OFSafety/overall frequency of adverse events (AEs)
measured Up to 24 months
Safety/dose limiting toxicities (DLTs)
measured Up to 28 days
Antitumor activity as measured by the objective response rate (ORR)
measured Through study completion, an average of 24 months
Publications
- PMID 39786390 — linked by the registry
- PMID 35366963 — linked by the registry
- PMID 34997701 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed